Component: (Network and Table)
Network
00100 - Statement - CONSOLIDATED BALANCE SHEETS
(http://www.immunogen.com/role/StatementConsolidatedBalanceSheets)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0000855654 (http://www.sec.gov/CIK)
CONSOLIDATED BALANCE SHEETSPeriod [Axis]
2016-06-30
2015-06-30
CONSOLIDATED BALANCE SHEETS
 
 
ASSETS
 
 
Cash and cash equivalents
245,026,000  
278,109,000  
Accounts receivable
883,000  
5,088,000  
Unbilled revenue
1,409,000  
714,000  
Inventory
907,000  
2,935,000  
Current portion of deferred financing costs
1,674,000  
1,159,000  
Prepaid and other current assets
4,881,000  
4,175,000  
Total current assets
254,780,000  
 
292,180,000  
 
Property and equipment, net of accumulated depreciation
22,704,000  
16,254,000  
Deferred financing costs, net of current portion
6,171,000  
4,415,000  
Other assets
3,430,000  
974,000  
Total assets
287,085,000  
 
313,823,000  
 
LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY
 
 
Accounts payable
11,510,000  
8,138,000  
Accrued compensation
10,724,000  
8,346,000  
Other accrued liabilities
9,713,000  
10,441,000  
Current portion of deferred lease incentive
772,000  
646,000  
Current portion of liability related to the sale of future royalties
15,138,000  
7,906,000  
Current portion of deferred revenue
13,582,000  
333,000  
Total current liabilities
61,439,000  
 
35,810,000  
 
Deferred lease incentive, net of current portion
6,236,000  
6,301,000  
Deferred revenue, net of current portion
19,288,000  
40,855,000  
Convertible 4.5% senior notes
100,000,000  
 
Liability related to the sale of future royalties, net of current portion
178,234,000  
191,756,000  
Other long-term liabilities
4,192,000  
3,997,000  
Total liabilities
369,389,000  
 
278,719,000  
 
Commitments and contingencies
xsi:nil  
xsi:nil  
Shareholders' (deficit) equity:
 
 
Preferred stock, $0.01 par value; authorized 5,000 shares; no shares issued and outstanding
xsi:nil  
xsi:nil  
Common stock, $0.01 par value; authorized 150,000 shares; issued and outstanding 87,209 and 86,579 shares as of June 30, 2016 and June 30, 2015, respectively
872,000  
866,000  
Additional paid-in capital
770,511,000  
743,108,000  
Accumulated deficit
(853,687,000) 
(708,870,000) 
Total shareholders' (deficit) equity
(82,304,000) 
 
35,104,000  
 
Total liabilities and shareholders' (deficit) equity
287,085,000  
 
313,823,000